Product nameAnti-VEGFD antibody
See all VEGFD primary antibodies
DescriptionRabbit polyclonal to VEGFD
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Macaque monkey
Synthetic peptide corresponding to Human VEGFD aa 300 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in HT1080 whole cell lysate as well as the following tissue lysates: Human Heart; Human Fetal Lung; Human Colon.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Note: Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab103685 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 40 kDa (predicted molecular weight: 40 kDa).|
|IHC-P||Use a concentration of 10 µg/ml.|
FunctionGrowth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
Tissue specificityHighly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas.
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
modificationsUndergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3 and VEGFR-2. VEGF-D first form an antiparallel homodimer linked by disulfide bonds before secretion. The fully processed VEGF-D is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.
- Information by UniProt
- c-fos induced growth factor antibody
- c-fos induced growth factor (vascular endothelial growth factor D) antibody
- c-fos induced growth factor antibody
All lanes : Anti-VEGFD antibody (ab103685) at 1 µg/ml
Lane 1 : HT 1080 (Human fibrosarcoma) Whole Cell Lysate
Lane 2 : Human heart tissue lysate - total protein (ab29431)
Lane 3 : Human Fetal Heart - Total Protein Tissue Lysate
Lane 4 : Human colon tissue lysate - total protein (ab30051)
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 40 kDa
Observed band size: 40 kDa
Additional bands at: 140 kDa, 45 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 8 minutes
Abcam recommends using milk as the blocking agent. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.
IHC image of VEGFD staining in Human heart muscle formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab103685, 10µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.